EMAIL THIS PAGE TO A FRIEND

Journal of thrombosis and haemostasis : JTH

Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count.


PMID 25876231

Abstract

Essential thrombocythemia (ET) is characterized by increased platelets and prevalent thrombosis. An acquired von Willebrand factor (VWF) disease has been hypothesized and inconsistently associated with extreme thrombocytosis or rare bleeding in ET.xa0Whether VWF is modified in ET patients with controlled platelet count remains unclear. We studied different VWF- and platelet-associated parameters in ET patients treated according to current recommendations. Sixty-nine ET patients (Mxa0=xa029; median age, 62 [48-70]xa0years; platelets, 432 [337-620]xa0×xa010(3) xa0μL(-1) ), 69 matched controls and 10 subjects with reactive thrombocytosis (RT) were studied. VWF:antigen (Ag), activity (act), electrophoretic patterns, VWF:propeptide, plasma glycocalycin (GC), glycoproteinV (GpV), ADAMTS-13, elastase, C-reactive protein and serum thromboxane (TX)B2 were measured. In ET patients, VWF:Ag was increased by 31xa0±xa013% vs. controls (Pxa0